{"id":"risankizumab-iv","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Upper respiratory tract infection"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL3990029","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting IL-23, risankizumab reduces the production of pro-inflammatory cytokines, thereby modulating the immune response and alleviating symptoms of autoimmune diseases.","oneSentence":"Risankizumab is a humanized monoclonal antibody that selectively binds to and blocks the interleukin-23 (IL-23) p19 subunit.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:32:16.044Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe plaque psoriasis"},{"name":"Active psoriatic arthritis"},{"name":"Moderate to severe Crohn's disease"}]},"trialDetails":[{"nctId":"NCT05995353","phase":"PHASE3","title":"A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease","status":"RECRUITING","sponsor":"AbbVie","startDate":"2023-12-11","conditions":"Crohn's Disease","enrollment":110},{"nctId":"NCT06548542","phase":"PHASE2","title":"Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease","status":"RECRUITING","sponsor":"AbbVie","startDate":"2024-09-04","conditions":"Crohn's Disease","enrollment":540},{"nctId":"NCT06880744","phase":"PHASE3","title":"A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-06-17","conditions":"Ulcerative Colitis","enrollment":530},{"nctId":"NCT07466550","phase":"PHASE1","title":"A Study to Assess How Intravenous and Subcutaneous Administrations of Risankizumab Moves Through the Body of Healthy Adult Participants","status":"NOT_YET_RECRUITING","sponsor":"AbbVie","startDate":"2026-03-08","conditions":"Healthy Volunteer","enrollment":60},{"nctId":"NCT07071519","phase":"PHASE3","title":"A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-07-28","conditions":"Ulcerative Colitis","enrollment":120},{"nctId":"NCT03105102","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2018-04-09","conditions":"Crohn's Disease","enrollment":1336},{"nctId":"NCT04524611","phase":"PHASE3","title":"Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2020-09-30","conditions":"Crohn's Disease (CD)","enrollment":527},{"nctId":"NCT05928039","phase":"PHASE4","title":"PATHFINDER: Evaluating the Optimal First-Line Treatment Strategy for Moderate-to-Severely Active Ileal-dominant Crohn's Disease","status":"RECRUITING","sponsor":"University of Calgary","startDate":"2023-10-25","conditions":"Crohn Disease","enrollment":297},{"nctId":"NCT06487572","phase":"PHASE1","title":"A Study to Assess Pharmacokinetic Exposures Following Intravenous and Subcutaneous Administration of Risankizumab in Healthy Participants","status":"COMPLETED","sponsor":"AbbVie","startDate":"2024-07-23","conditions":"Healthy Volunteers","enrollment":60},{"nctId":"NCT03398148","phase":"PHASE2, PHASE3","title":"A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Ulcerative Colitis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2018-03-07","conditions":"Ulcerative Colitis (UC)","enrollment":1558},{"nctId":"NCT05169593","phase":"PHASE4","title":"Prevention of Postoperative Endoscopic Recurrence with Endoscopy-driven Versus Systematic Biological Therapy","status":"RECRUITING","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2022-09-08","conditions":"Crohn Disease","enrollment":292},{"nctId":"NCT06298188","phase":"NA","title":"Risankizumab in Children With Crohn's Disease (RisaKids)","status":"RECRUITING","sponsor":"Shaare Zedek Medical Center","startDate":"2024-10-31","conditions":"Crohn Disease","enrollment":90},{"nctId":"NCT04254783","phase":"PHASE1","title":"A Study to Evaluate the Effect of Intravenous (IV) Infusions of Risankizumab on Pharmacokinetics of Cytochome P450 Substrates in Adult Participants With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease","status":"COMPLETED","sponsor":"AbbVie","startDate":"2020-05-27","conditions":"Ulcerative Colitis (UC), Crohn's Disease","enrollment":20},{"nctId":"NCT04583956","phase":"PHASE2","title":"ACTIV-5 / Big Effect Trial (BET-A) for the Treatment of COVID-19","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-10-23","conditions":"COVID-19","enrollment":214},{"nctId":"NCT03105128","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-05-10","conditions":"Crohn's Disease","enrollment":931},{"nctId":"NCT03104413","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-12-18","conditions":"Crohn's Disease","enrollment":618},{"nctId":"NCT05305222","phase":"PHASE1","title":"A Study in Healthy Japanese and Caucasian Subjects to Assess the Pharmacokinetics, Safety and Tolerability of Risankizumab","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-10-23","conditions":"Healthy Volunteers","enrollment":17},{"nctId":"NCT05268068","phase":"PHASE1","title":"A Study of Intravenously (IV) Infused or Subcutaneously (SC) Injected Risankizumab in Healthy Adult Participants in China","status":"COMPLETED","sponsor":"AbbVie","startDate":"2019-06-27","conditions":"Healthy Volunteers","enrollment":30},{"nctId":"NCT02513459","phase":"PHASE2","title":"A Long Term Extension Trial of BI 655066/ABBV-066 (Risankizumab), in Patients With Moderately to Severely Active Crohn's Disease","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-09-16","conditions":"Crohn Disease","enrollment":65},{"nctId":"NCT02031276","phase":"PHASE2","title":"Efficacy, Safety and Pharmacokinetics of BI 655066/ABBV-066 (Risankizumab) in Patients With Active, Moderate-to-severe Crohn's Disease.","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-02","conditions":"Crohn Disease","enrollment":121},{"nctId":"NCT02596217","phase":"PHASE1","title":"Safety, Tolerability and Pharmacokinetics of BI 655066/ABBV-066 (Risankizumab) in Healthy Asian and Caucasian Male Volunteers","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-08","conditions":"Healthy","enrollment":80}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":16,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ABBV-066 BI 655066","SKYRIZI","BI 655066","ABBV-066"],"phase":"phase_3","status":"active","brandName":"risankizumab IV","genericName":"risankizumab IV","companyName":"AbbVie","companyId":"abbvie","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Risankizumab IV is an interleukin-23 inhibitor, a type of antibody that belongs to the drug class of inhibitors. It is being studied for the treatment of Crohn's Disease and Ulcerative Colitis, among other conditions.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":3},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}